You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Autophagy-associated genes appear to be important for immune evasion, but losing multiple of these genes could also make cancers resistant to T cell activity.
Under the non-exclusive deal, Oxford Nanopore can include the technology, which targets long DNA fragments, in its nanopore sequencing products.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
The company said it will use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips.
The company's technology uses CRISPR to deplete unwanted nucleic acid sequences from NGS libraries, leaving behind targets of interest.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.
In Nature this week: analysis of the effect of plasma proteins on disease phenotypes, and more.
An international committee finds genome editing is not yet ready to be used on human embryos.
The panel also said that if any nation does decide to allow germline genome editing, its use should be limited to preventing serious monogenic diseases.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.